Glp-1 Receptor Agonist Mortality Benefits

This is the largest meta-analysis of placebo-controlledGLP-1RA randomized controlled trials to report cardiovascular and renal outcomes among patients with and without diabetes mellitus.GLP-1RAs significantly reduced MACE, all-causemortality, CV ...

GLP-1receptoragonists, regardless of structural homology, reduced the risk of individual MACE components, all-causemortality, hospital admission for heart failure, and worsening kidney function in patients with type 2 diabetes.

BACKGROUND Glucagon-like peptide1receptoragonists(GLP-1RA) reduce the incidence of major adverse cardiovascular events (MACE) in type 2 diabetes (T2D), although whetherbenefitsextend to both subcutaneous and oral formulations remains unclear.

As we can see from the illustration, Glp-1 Receptor Agonist Mortality Benefits has many fascinating aspects to explore.

Here, the authors show thatGLP-1RAs are associated with reducedmortalityand improved cardio-renal outcomes in type 2 diabetes patients with acute kidney disease.

In 2005, exenatide was the firstGLP-1receptoragonist(GLP-1RA) medication that was approved by the US Food and Drug Administration (FDA) to treat T2D. 2 Since the discovery ofGLP-1and the development of exenatide, our understanding ofGLP-1receptorexpression and subsequent drug development has undergone a remarkable evolution.

This particular example perfectly highlights why Glp-1 Receptor Agonist Mortality Benefits is so captivating.

Cardiovascular,mortality, and kidney outcomes withGLP-1receptoragonistsin patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials

GLP-1(glucagon-like peptide-1)receptoragonistsand SGLT2 (sodium-glucose cotransporter 2) inhibitors both improve cardiovascular and kidney outcomes in people with type 2 diabetes. We conducted a systematic review and meta-analysis to assess the effects ofGLP-1receptoragonistson clinical outcomes with and without SGLT2 inhibitors.

Because of thesebenefits, doctors are recommendingGLP-1receptoragonistsfor people with type 2 diabetes who are at a high risk of strokes and heart-related deaths.